pharmaphorum2 天
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK
The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by rejecting AstraZeneca’s PT010, a close competitor. AZ has confirmed ...